Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P050019/S043

Carotid Wallstent Monorail Endoprosthesis

Boston Scientific Corp · Decision date Sep 19, 2025

FDA DECISIONP050019/S043

What did the FDA approve?

FDA records P050019/S043 as a supplement to PMA P050019, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Sep 19, 2025.

FDA approval order statement

approval for changes to the manufacturing process intended to increase the potential for consistently producing an inner guidewire lumen within the specified height
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Sep 19, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P050019/S043
Regulatory pathway
PMA supplement
Product code
NIM
Decision code
APPR
Decision date
Sep 19, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, carotid.

Product code
NIM
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P050019/S043 received

    Application receipt date recorded by FDA.

  2. P050019/S043 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P050019. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code NIM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
Three Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records